Sellas Life Sciences is trading 4.08% up now at $12.25 as investors continued digesting its August 11 earnings release and clinical update.
- Management highlighted the approaching 80th event in the Phase 3 REGAL trial, triggering final-analysis procedures.
- Cash stood at $138.3 million, with Q4 2026 SLS009 topline data expected.
- No separate August 13 company announcement was identified; broader risk-on sentiment may also be supportive.